ClinVar Miner

Submissions for variant NM_144997.7(FLCN):c.1286dup (p.His429fs) (rs879255675)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Division of Genomic Diagnostics,The Children's Hospital of Philadelphia RCV000239666 SCV000298077 pathogenic Multiple fibrofolliculomas 2016-07-18 criteria provided, single submitter clinical testing
GeneDx RCV000413427 SCV000490529 pathogenic not provided 2017-07-18 criteria provided, single submitter clinical testing The c.1286dupA variant in the FLCN gene has been reported previously in association with Birt-Hogg-Dube syndrome (Toro et al., 2008; Maffe et al., 2011). The duplication causes a frameshift starting with codon Histidine 429, changes this amino acid to a Glutamine residue and creates a premature Stop codon at position 27 of the new reading frame, denoted p.His429GlufsX27. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Based on currently available evidence, we consider c.1286dupA to be pathogenic, and its presence consistent with a diagnosis of Birt-Hogg-Dube syndrome.
Invitae RCV000239666 SCV000549466 pathogenic Multiple fibrofolliculomas 2017-06-06 criteria provided, single submitter clinical testing This sequence change inserts 1 nucleotide in exon 11 of the FLCN mRNA (c.1286dupA), causing a frameshift at codon 429. This creates a premature translational stop signal (p.His429Glnfs*27) and is expected to result in an absent or disrupted protein product. Loss-of-function variants in FLCN are known to be pathogenic. This particular variant has been reported in the literature in an individual with Birt-Hogg-Dubé (BHD) syndrome (PMID: 18234728). This variant is also known as c.1741insA in the literature. A different variant, c.1285dupC (p.His429Profs*27), which results in the same truncated protein as the one observed here, has been reported in individuals affected with BHD syndrome (PMID: 18234728). It has been shown to affect the protein stability and tumor suppressor activity of the FLCN protein in cell culture (PMID: 21538689). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.